EMBC Legal Deadline Notice: Important Embecta Deadline in Securities Fraud Class Action is Approaching – Investors Notified to Contact BFA Law by August 17

A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.

A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit .

Key Details of the Embecta ($EMBC) Class Action:

Lead Plaintiff Deadline: August 17, 2026

Alleged Misconduct: Securities fraud relating to Embecta’s statements about the strength of its insulin pen needle product category.

Largest Alleged Stock Drop: May 5, 2026 – 57.8% Stock Drop

Court: U.S. District Court for the District of New Jersey

Action: Contact BFA Law to discuss your rights

Investors have until August 17, 2026 to ask the Court to be appointed to lead the case.

The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock.

The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Apitz-Grossman v. Embecta Corp., et al. , No. 26-cv-07217.

Why is Embecta Being Sued for Securities Fraud?

Embecta is a medical device company that produces insulin pens for patients with diabetes.

According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that “prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio.”

As alleged, in truth, Embecta faced significant competition and “overall market softness for insulin pens and pen needles.”

Why did Embecta’s Stock Drop?

On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer.

Embecta also reported an “overall market volume softness for insulin pens and pen needles in the retail channel,” admitting that “we have now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported.”

As a result, Embecta also reduced its quarterly dividend from $0.15 to $0.01 per share.

This news caused the price of Embecta common stock to decline $5.35 per share, or 57.8%, from $9.25 per share on May 4, 2026, to $3.90 per share on May 5, 2026.